anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
No statins is assigned to patients for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
The aim of the study is to determine the effect of a low volume high intensity interval training (HIIT) exercise intervention on cardio-respiratory fitness (CR-fitness), insulin resistance, and cognitive function among normally active but physically untrained HIV+ Hispanic women. The primary hypotheses are that HIIT will improve: 1) CR-fitness in all groups (HIV+ and HIV-), 2) insulin sensitivity in both groups of HIV+ women, and 3) cognitive function as determined by hippocampal function in HIV+ women with HAND. Participants will receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts. Then, participants will be evaluated with a CR-fitness, insulin resistance, anthropometry, and neurocognitive function tests.

Participants will undergo an intervention (described above) designed for normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neurocognitive impairment \& HIV- controls (n=15). After the HIIT intervention, measurements of CR-fitness, insulin resistance, and cognitive function including hippocampal function using the memory island test will be obtained, as well as CR-fitness, anthropometry, DEXA densitometry, and blood and urine samples for metabolic testing. The ultimate goal is to improve the understanding of mechanisms by which exercise influence neurocognitive function; thus, providing a potential non-pharmacological alternative to prevent, control or reduce chronic incapacitating diseases in HIV+ Hispanic adults.
Lipopolysaccharide (LPS), a unique component of the outer membrane of Gram-negative bacteria, possesses immune-activating properties. It induces an immune response by stimulating host cells to produce a lot of inflammatory cytokines with a thermogenic effect, which may cause an inflammatory response. In the past few decades, the structure and function of LPS and its mechanism leading to inflammation have been extensively analyzed. Since LPS can cause inflammation, it is often used to establish inflammation models. These models are crucial in the study of inflammatory diseases that pose a serious threat to human health. In addition, the non-pro-inflammatory effects of LPS under certain circumstances are also being studied widely. This review summarizes the methods by which LPS has been used to establish inflammatory models at the cellular and animal levels to study related diseases. It also introduces in detail the evaluation indicators necessary for the successful establishment of these models, providing a reference for future research.
Methods for the ex vivo use of NAD to remove T cells that can potentially cause graft-verus-host disease (GvHD) from hematopoietic stem cell sources. Hematopoietic stem cell sources include bone marrow, cord blood, and peripheral blood (including mobilized peripheral blood). The present invention is a method including steps for using the hematopoietic stem cell sources treated with NAD for hematopoietic stem cell transplants (HSCTs). HSCTs are used as the standard-of-care in many diseases including several types of cancer and several genetic disorders. The majority of these transplants are allogeneic, in which the stem cell source comes from a donor who is a different individual than the intended recipient. Allogeneic HSCTs carry a risk of causing GvHD, in which donor T cells attack the recipient.
All volunteers completed a pre-test, which includes an additional two scales along with the sociodemographic data form, and two post-tests, which only include the scales. Both groups will receive the Child Abuse and Neglect Awareness Training, which will last approximately 60 minutes. Both groups will complete the pre-test and post-tests at the same time. However, immediately after the pre-test, the experimental group will receive the training and then complete the 1st post-test, followed by the 2nd post-test one month later. Additionally, the second post-test will be administered to both groups simultaneously one month after the completion of the first post-test. After the completion of all the tests, the control group also received the same training, and both groups received participation certificates. Apart from these tasks, there are no other responsibilities.
The psychoeducation group consists of 10 sessions of approximately 1.5 hours each, once a week or every two weeks depending on the availability of the therapists. Among the sessions, 9 correspond to a specific theme: reminder of the law and violence, sexism, consent, control, social pressure, self-control, empathy, seduction and romantic relationships, sex under the influence. The last session is devoted to a resumption of all the themes previously discussed. Semi-structured qualitative interviews addressing their feelings regarding the psychoeducation group, what they learned from it, what they had difficulty with.
Uric acid levels often rise when kidney function declines. Historically, high uric acid has not been treated unless the uric acid crystallizes in the joint space and causes clinical gout disease, more typically seen in adults. However, new research has shown that high uric acid levels are associated with the development of hypertension, inflammation, and both acute and chronic kidney injury. Adult patients on renal dialysis who have hyperuricemia also have higher mortality rates. In several adult and in one pediatric clinical trial of uric acid lowering therapy (with Allopurinol or Febuxostat), treatment has demonstrated a slower rate of renal function decline and improved blood pressure compared to placebo. The pediatric trial was a 4-month placebo controlled trial of Allopurinol, and showed positive improvement in renal function and blood pressure, but did not adequately control for potential confounders in the outcome. Two known confounders that influence renal function (glomerular filitration rate, GFR) in pediatric CKD are race and glomerular or non-glomerular disease etiology. This study is designed to control for these confounders and establish whether Allopurinol for 6 months of treatment to a goal range of 3-5 mg/dL will improve renal function compared to standard of care. The secondary outcome is to determine whether blood pressure is affected by the treatment and the magnitude of change of serum uric acid. This study will also explore whether Allopurinol treatment alters activation of the Nlrp3 inflammasome or renal injury biomarkers.
Reactive changes of glial cells during neuroinflammation impact brain disorders and disease progression. Elucidating the mechanisms that control reactive gliosis may help us to understand brain pathophysiology and improve outcomes. Here, we report that adult ablation of autism spectrum disorder (ASD)-associated CHD8 in astrocytes attenuates reactive gliosis via remodeling chromatin accessibility, changing gene expression. Conditional Chd8 deletion in astrocytes, but not microglia, suppresses reactive gliosis by impeding astrocyte proliferation and morphological elaboration. Astrocyte Chd8 ablation alleviates lipopolysaccharide-induced neuroinflammation and septic-associated hypothermia in mice. Astrocytic CHD8 plays an important role in neuroinflammation by altering the chromatin landscape, regulating metabolic and lipid-associated pathways, and astrocyte-microglia crosstalk. Moreover, we show that reactive gliosis can be directly mitigated in vivo using an adeno-associated virus (AAV)-mediated Chd8 gene editing strategy. These findings uncover a role of ASD-associated CHD8 in the adult brain, which may warrant future exploration of targeting chromatin remodelers in reactive gliosis and neuroinflammation in injury and neurological diseases.
Background: Nirmatrelvir/Ritonavir is an orally administered anti-SARS-Cov-2 drug used in mild-to-moderate COVID-19 patients. Our retrospective cohort study aims to evaluate the efficacy and safety of Nirmatrelvir/Ritonavir in severe hospitalized patients with Omicron infection, as well as in patients at high risk for progression to critical illness in real-world settings. Methods: A total of 350 patients received Nirmatrelvir/Ritonavir while 350 matched controls did not. Patients with confirmed COVID-19 were administered Nirmatrelvir 300 mg and Ritonavir 100 mg orally twice a day for 5 days, with the medication initiated on the first day after admission. The primary endpoint of the study was a composite outcome of hospitalization or death from any cause within 28 days. Secondary endpoints included the occurrence of adverse events and the evaluation of serum levels of IL-6 and viral load. Results: We documented the mortality risk from any cause within 28 days, viral load, serum IL-6 levels, and adverse events. Nirmatrelvir/Ritonavir reduced the 28-day risk of all-cause mortality by 86% (P = .011, hazard ratio (HR) = 0.14, 95% confidence interval (CI) = 0.03, 0.64). At baseline, the serum level of IL-6 was significantly higher in the antiviral treatment group compared to the control group (P < .001), but no significant difference (P = .990) was found between the two groups at discharge. In CKD patients undergoing hemodialysis, no significant worsening of renal function was observed in the Nirmatrelvir/Ritonavir treatment group compared to the control group. Conclusion: Nirmatrelvir/Ritonavir may reduce the 28-day risk of all-cause mortality in critically ill patients with COVID-19 and in patients at high risk for critical disease progression.
Composition comprises cosmetic active ingredients encapsulated in liposome. The liposome comprises phospholipid and glycolipid. The glycolipid comprises a hydrophobic unit, and a carbohydrate unit including an oligomer or a polymer of fructose. A mass ratio of phospholipid and glycolipid is 0.5-30, preferably 1-10. The composition is free of L-ornithine and/or its salt or ester. Independent claims are included for: (1) a cosmetic product; and (2) the liposome comprising phospholipid and glycolipid.
Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
BACKGROUND: Developing wheat cultivars with durable resistance to powdery mildew, caused by Blumeria graminis f. sp. tritici (Bgt), is crucial for sustainable agriculture. The wheat genotype MYC exhibited high resistance to the Bgt isolate E09 at the seedling stage. Genetic analysis identified a recessive gene, temporarily named PmMYC, responsible for this resistance. Understanding the molecular mechanisms underlying this resistance is essential for advancing breeding programs.
RESULTS: Bulked Segregant RNA-Seq revealed numerous alternative splicing events generated following Bgt infection, suggesting powdery mildew may disrupt alternative splicing and affect immune responses. Gene Ontology (GO) analysis indicated significant enrichment of differentially expressed genes in "response to stimuli" and "immune system processes", implying their roles in disease defense. BSR-Seq analysis identified two high-confidence candidate regions for PmMYC on chromosome 2B, spanning 40,451,950 - 102,426,703 bp and 421,707,046-449,840,516 bp. Within these intervals, 740 genes were identified, with nonsynonymous mutations in 46 genes in the parents and bulks. Real-time PCR showed distinct expression profiles in four genes in resistant MYC compared to susceptible Yannong 21. KEGG and COG analyses of differentially expressed genes in candidate intervals revealed enrichment in immune processes related to plant-pathogen interactions, confirming that PmMYC initiated a broad immune response to prevent Bgt invasion.
CONCLUSION: The study identified key genetic intervals and genes involved in the resistance of wheat genotype MYC to Bgt. The identified genes, particularly those with altered expression profiles, could serve as valuable targets for breeding programs aimed at developing wheat cultivars with durable resistance to powdery mildew. These findings enhanced our understanding of plant-pathogen interactions and provided a foundation for future genetic and functional studies.
The present disclosure is directed to compositions of materials and methods of making those compositions. These compositions include cellulose materials that may be consumed by an animal without chewing. Compositions of the present disclosure may also include coatings that resist dissolution in the mouth of an animal, yet readily dissolve in the digestive tract of an animal or human/person. The present disclosure is also directed to administering selected compositions to treat specific ailments or conditions that may affect animals or humans. Such treatments include treating conditions related to improving gut health, reducing neuro-inflammation, and treating metabolic diseases. Additionally, such treatments include the stimulation, enhancement and/or compatibility with microbiota and the effects of microbiota on diseases and conditions, such as gut health of an animal, including a human.
PURPOSE: This study compared the interrater reliability of adult naïve listeners' perceptual assessments of different speech variables in children with a cleft palate with or without a cleft lip (CP ± L). In addition, the study investigated whether the listeners were able to perceive differences in these speech variables before and after speech therapy for cleft palate speech disorders.
METHOD: Thirty-four speech samples of 14 children with a CP ± L (14 samples collected immediately before 10 hr of speech intervention, 14 samples collected immediately after speech intervention, and six randomly selected samples that were duplicated to assess intrarater reliability) were perceptually assessed by 26 adult naïve listeners. The listening panel consisted of nine men and 17 women (age range: 18-51 years). The speech variables included speech understandability, speech acceptability, hypernasality, hyponasality, nasal airflow, and articulation, which were assessed on a visual analog scale. Furthermore, the need for speech therapy was assessed.
RESULTS: Good to very good interrater reliability was observed for the naïve listeners' ratings of all speech variables. A significant time effect was found for the pre- and postevolution of the speech variables "speech understandability," "speech acceptability," "nasal airflow," and "articulation." This time effect indicates an improvement of these variables postintervention. According to the naïve listeners, children were less in need of additional speech therapy after the 10-hr intervention period compared to assessments before this intervention period.
CONCLUSIONS: Adult naïve listeners perceptually identified an improvement in different speech variables after 10 hr of cleft palate speech therapy. These findings confirm previous assessments of expert speech-language pathologists and suggest that speech improvements after cleft palate speech therapy can also be perceived by communication partners outside the therapy room. Perceptual ratings of naïve listeners can, thus, be used to add life-situation significance to the assessments of experts. Future research could include both expert raters and caregivers or relatives of children with a CP ± L in listening panels, as previous knowledge on craniofacial anomalies may lead to different results.
The invention belongs to the technical field of medicines and particularly relates to an ambroxol hydrochloride composition and a preparation thereof. The composition comprises the following components in parts by weight: 15 parts of ambroxol hydrochloride, 50-150 parts of mannitol, 1-10 parts of meglumine and 0.05-0.5 part of ethylene diamine tetraacetic acid disodium. The preparation is injection. Every injection contains 15mg of ambroxol hydrochloride, 50-150mg of mannitol, 1-10mg of meglumine, 0.05-0.5mg of ethylene diamine tetraacetic acid disodium and 2ml of water for injection. The invention provides the safe and stable ambroxol hydrochloride preparation. Proved by stability tests, the stability of the ambroxol hydrochloride preparation is superior to that of preparations in the prior art.
A novel therapy for Pseudomonas aeruginosa infections, in particular in cystic fibrosis patients, is described. Macrophages provide the first line of defence in protecting the lung against bacterial infections. Nonetheless, Pseudomonas aeruginosa infections continue to be problematic in cystic fibrosis patients and are the leading cause of death in these patients. Previously, little was known regarding the factors which regulate the capacity of macrophages to mediate phagocytosis of Pseudomonas aeruginosa. The inventors have now shown that phagocytosis of nonopsonized Pseudomonas aeruginosa by macrophages is dependent upon the presence of glucose. They have also shown that the action of glucose is on the macrophage rather than the bacteria. Glucose therapy can therefore be used to prevent or combat Pseudomonas aeruginosa infections.
The invention relates to the field of daily chemicals, in particular to a hair growing and blackening herbal composition. The composition belongs to a natural herbal preparation, and is prepared from ginseng, lucid ganoderma, rhizoma polygonati, cacumen biotae, herba ecliptae, ligusticum wallichii, black bean, black sesame, rhizoma gastrodiae, polygonum multiflorum, notopterygium root, medlar, black mulberry, schisandra chinensis, glossy privet fruit, semen cuscutae, raspberry, safflower and the like according to a certain proportion. Most of the products are liver and kidney tonifying, wind dispelling and dampness removing, blood circulation invigorating and stasis removing, and a few resuscitation inducing and dryness regulating antibacterial products, and have no toxic or side effect and adverse reaction. By applying the composition, liquid permeates into the part under the scalp cortex, improves the microcirculation system of the scalp cortex, is dissolved into the whole blood circulation of a human body, activates liver blood, and is capable of dredging channels and collaterals, thereby supplementing nutrient components at the root of hair follicles, enabling the hair follicles lacking nutrients and closed hair follicles to reappear vitality, and promoting the regeneration of new black white hair. The quick-acting rate of the medicine takes effect basically in 15 to 50 days. Simultaneously has the effects of treating tinea capitis and dermatitis, removing dandruff and relieving itching; also has remarkable effect on hair dryness, bifurcation and fracture.
Subjects belonging to the control group will receive the same amount of therapy (12 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an "entry level," and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback.
PURPOSE:To develop the method for prepn. of the sustained-releasable microcapsule capable of adjusting the amt. of a core material penetrating the inside of a capsule membrane by once preparing the microcapsule, then treating this microcapsule to form the routes for permeation of the core material in the microcapsule membrane. CONSTITUTION:The sustained release property is imparted to the microcapsule 4 by adjusting the pH of a microcapsule dispersion to an alkaline region after the prepn. of the microcapsule dispersion prepd. by using such an emulsifier 2 which increases solubility in the alkaline region.
Chronic Obstructive Pulmonary Disease (COPD) is a complex and heterogeneous condition. Exposure to tobacco smoke and air pollutants are key risk factors for COPD development; however, other risk factors include race/ethnicity, sex of adults, a history of asthma, occupational exposures, and chronic respiratory infections. Data for the current study were from the 2022 Behavioral Risk Factor Surveillance Survey. Chi-squares and multinomial logistic regression analyses, adjusted with the survey's sampling weight, were used to examine how critical health indicators impacted a COPD diagnosis. Participants (N = 311,175) were adults aged 45 years and older. Adjusted multinomial regression analyses showed adults who reported asthma, current and former smoking, poor physical health, depression, less physical activity, and fatigue were more likely to report COPD. Those with COPD were more likely to be male than female. Moreover, those with COPD reported higher rates of health insurance coverage, and yet had lower income and more financial difficulty affording a doctor for health services. In a follow up regression analysis, examining racial differences in COPD for participants, American Indian adults had a higher odds of reporting COPD than the "other" race groups. Because COPD remains a leading cause of death and disability in the U.S., and racial disparities persist in respiratory outcomes, continuing to identify risk factors for vulnerable groups could assist health program planners with development of successful health messaging.
PURPOSE:To provide a cleansing agent for removing rouge, containing a specific aliphatic monoethanolamide surfactant as a main ingredient, or containing the surfactant and a specific propylene glycol surfactant and/or a specific amphoteric surfactant as main components. CONSTITUTION:A cleansing agent for removing rouge is characterized by containing an aliphatic monoethanolamide surfactant of formula I (R is alkyl; n is 3-8) (e.g. Amizett 5C) as a main ingredient. A cleansing agent for removing rouge is characterized by combining the cleansing agent with an ethyleneoxide- added polypropylene glycol surfactant of formula II (a-c are integers, a+b=5-200, and b= 5-100) or an amphoteric surfactant (especially preferably imdazolinium betaine). Otherwise, the cleansing agent for removing rouge contains the surfactant of formula I, the ethyleneoxide-added polypropylene glycol surfactant, and the amphoteric surfactant. The cleansing agents are excellent in rouge-removing effect and high in safety and stability. Further, the cleansing agents do not bleed out on their employment and exhibit smooth using touch.